Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$118.24

-5.76 (-4.65%)

12:18
03/25/19
03/25
12:18
03/25/19
12:18

Sarepta treatment shows 'impressive' improvement at 9 months, says Needham

After Sarepta presented updated 9 month data from four boys in a study testing their micro-dystrophin gene therapy, Needham analyst Chad Messer said "impressive" functional improvement was observed in all four patients and that levels of creatinine kinase, which is a measure of muscle damage, were generally improved and below levels normally associated with Duchenne. Messer maintains a Buy rating and $196 price target on Sarepta shares.

  • 25

    Mar

  • 19

    Aug

SRPT Sarepta
$118.24

-5.76 (-4.65%)

03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
03/25/19
HCWC
03/25/19
NO CHANGE
Target $267
HCWC
Buy
Sarepta data bode well for registration study, says H.C. Wainwright
The functional gains with Sarepta Therapeutics' SRP-9001 in this morning's data bode well for the registration study, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. Micro-dystrophin gene therapy appears to positively impact key functional endpoints with a 34% increase in NSAA scores, and a -20%, -29%, and -13% change in time to rise, four-minute stair climb, and time to 100 meters, respectively from baseline to day 270, says the analyst. While bears are likely to point to the large variability in CK, a 64% decline from baseline, while not quite the 90%-plus at an earlier time point, for a measurement that is uniquely susceptible to activity is more an attribute of increased functional capacity as opposed to waning of gene therapy's effectiveness hypothesis in the younger patients, contends Chattopadhyay. He has a Buy rating on Sarepta with a $267 price target.
03/25/19
JPMS
03/25/19
NO CHANGE
JPMS
Overweight
Data today reinforce Sarepta's 'pole position,' says JPMorgan
The updated data from the first four Duchenne muscular dystrophy patients of Sarepta Therapeutics' Phase 1/2 trial at nine months are "all directionally positive" on both biomarker and functional assessments, JPMorgan analyst Anupam Rama tells investors in a research note. The analyst is not surprised with the creatine kinase fluctuations as patients become more active and finds it important that all biomarker/functional endpoints were improved from baseline at nine months. While lingering questions about competition in the micro-dystrophin space remain, these data reinforce Sarepta's "pole position," Rama contends. He keeps an Overweight rating on the shares. The stock in morning trading is down 4%, or $4.53, to $117.73.
03/25/19
RBCM
03/25/19
NO CHANGE
Target $192
RBCM
Outperform
Sarepta data does not change thesis on DMD program, says RBC Capital
RBC Capital analyst Brian Abrahams notes that Sarepta Theraputics this morning reported nine-month functional and creatine kinase data from baseline from the four patients in the Phase 1 open-label study of the company's micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy. Overall, Abrahams says the results show continued improvements in North Star Ambulatory Assessment functional scores vs. the baseline, and that while the update may not stop concerns, it does not change his overall thesis on the program, where he continues to believe the totality of expression, biomarker and functional data point to real benefits that should enable improvements supporting approval in ongoing/subsequent studies. Abrahams, who has an Outperform rating and $192 price target on Sarepta, says he would use weakness as a buying opportunity.

TODAY'S FREE FLY STORIES

ALGT

Allegiant Travel

$172.80

0.57 (0.33%)

11:06
12/11/19
12/11
11:06
12/11/19
11:06
Hot Stocks
Allegiant Travel reports November scheduled service RPMs up 1.6% »

Allegiant Travel reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$251.05

-0.74 (-0.29%)

11:05
12/11/19
12/11
11:05
12/11/19
11:05
Hot Stocks
Huntington Ingalls appoints Bharat Amin as EVP, CIO »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$35.35

0.65 (1.87%)

11:05
12/11/19
12/11
11:05
12/11/19
11:05
Options
Ciena call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMZN

Amazon.com

$1,738.75

-0.4 (-0.02%)

11:01
12/11/19
12/11
11:01
12/11/19
11:01
Periodicals
Alexa devices sell out in parts of Europe before Christmas, Bloomberg reports »

Amazon's new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVER

EverQuote

$34.09

-1.95 (-5.41%)

11:01
12/11/19
12/11
11:01
12/11/19
11:01
On The Fly
EverQuote down after Bonitas says it expects stock to drop to about $5 »

Shares of EverQuote…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:01
12/11/19
12/11
11:01
12/11/19
11:01
Conference/Events
JPMorgan banking analyst to hold an analyst/industry conference call »

U.S. Mid & Small Cap…

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:59
12/11/19
12/11
10:59
12/11/19
10:59
Hot Stocks
Breaking Hot Stocks news story on LogMeln 

LogMein trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:58
12/11/19
12/11
10:58
12/11/19
10:58
Hot Stocks
LogMeln up 6% after report of private equity takeover talks »

Shares of LogMeIn are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:55
12/11/19
12/11
10:55
12/11/19
10:55
Periodicals
PE firms in talks to buy LogMeln, Bloomberg says »

Francisco Partners and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$7.89

-0.06 (-0.75%)

10:55
12/11/19
12/11
10:55
12/11/19
10:55
Options
SmileDirectClub put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWI

SolarWinds

$18.07

-0.11 (-0.61%)

10:55
12/11/19
12/11
10:55
12/11/19
10:55
Conference/Events
SolarWinds to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LOGM

LogMeln

$74.20

0.24 (0.32%)

10:54
12/11/19
12/11
10:54
12/11/19
10:54
Hot Stocks
Breaking Hot Stocks news story on LogMeln »

LogMein trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XP

XP

$0.00

(0.00%)

10:53
12/11/19
12/11
10:53
12/11/19
10:53
Syndicate
Breaking Syndicate news story on XP »

XP indicated to open at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MNST

Monster Beverage

$62.03

0.51 (0.83%)

10:45
12/11/19
12/11
10:45
12/11/19
10:45
Options
Monster Beverage call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/11/19
12/11
10:45
12/11/19
10:45
General news
Energy Action: WTI crude »

Energy Action: WTI crude…

CI

Cigna

$190.86

-0.88 (-0.46%)

, CVS

CVS Health

$73.06

-0.11 (-0.15%)

10:42
12/11/19
12/11
10:42
12/11/19
10:42
On The Fly
Cigna downgrade, Apple, PC&G target raises among today's top calls »

Check out today's top…

CI

Cigna

$190.86

-0.88 (-0.46%)

CVS

CVS Health

$73.06

-0.11 (-0.15%)

AMZN

Amazon.com

$1,740.89

1.74 (0.10%)

NFLX

Netflix

$298.30

5.09 (1.74%)

UPS

UPS

$117.55

-0.94 (-0.79%)

PCG

PG&E

$12.94

0.61 (4.95%)

AAPL

Apple

$270.44

1.82 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 06

    Feb

ALKS

Alkermes

$21.49

-0.08 (-0.37%)

10:40
12/11/19
12/11
10:40
12/11/19
10:40
Hot Stocks
FDA issues warning letter to Alkermes over print ad for Vivitrol »

In a warning letter dated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$26.39

0.1 (0.38%)

10:35
12/11/19
12/11
10:35
12/11/19
10:35
Options
NortonLifeLock put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EVER

EverQuote

$35.00

-1.04 (-2.89%)

10:33
12/11/19
12/11
10:33
12/11/19
10:33
Periodicals
EverQuote named as short idea by Bonitas Research 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XP

XP

$0.00

(0.00%)

10:30
12/11/19
12/11
10:30
12/11/19
10:30
Syndicate
Breaking Syndicate news story on XP »

XP indicated to open at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

USO

United States Oil Fund

$12.35

-0.04 (-0.32%)

10:30
12/11/19
12/11
10:30
12/11/19
10:30
General news
Crude inventories for week of December 6 »

Crude oil inventories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$191.14

-0.6 (-0.31%)

, MET

MetLife

$49.25

-0.04 (-0.08%)

10:28
12/11/19
12/11
10:28
12/11/19
10:28
On The Fly
Street Fight: Cigna sparks analyst debate over PillPack news, possible unit sale »

Shares of Cigna (CI) are…

CI

Cigna

$191.14

-0.6 (-0.31%)

MET

MetLife

$49.25

-0.04 (-0.08%)

SLF

Sun Life Financial

$44.82

0.04 (0.09%)

WBA

Walgreens Boots Alliance

$57.92

-0.48 (-0.82%)

WCG

WellCare

$317.16

-2.3 (-0.72%)

ACHC

Acadia

$31.73

-0.37 (-1.15%)

EHC

Encompass Health

$70.90

-0.88 (-1.23%)

ANTM

Anthem

$281.14

-2.45 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 08

    Jan

  • 06

    Feb

  • 13

    Feb

XP

XP

$0.00

(0.00%)

10:24
12/11/19
12/11
10:24
12/11/19
10:24
Syndicate
XP indicated to open at $34.00, IPO priced at $27.00 »

XP (XP) priced 72.5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:22
12/11/19
12/11
10:22
12/11/19
10:22
Conference/Events
JPMorgan healthcare tech analyst to hold an analyst/industry conference call »

Healthcare Technology…

F

Ford

$9.12

0.045 (0.50%)

10:20
12/11/19
12/11
10:20
12/11/19
10:20
Options
Long-dated put sale in Ford sold tied to hedge possibly closes »

Long-dated put sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 04

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.